|
Dr. Goelet is a founding member of Red Abbey. Dr. Goelet formed his relationship with Mr. Bonsal in 1990 when he joined the Board of Directors of Molecular Tool, Inc., a Baltimore, MD based life sciences company that was founded by Dr. Goelet. In 1997, Mr. Bonsal and Dr. Goelet launched their personal life sciences investment program, as described in Historical Investment Activity and Performance. Dr. Goelet is a scientist, entrepreneur, and investor, with research experience in molecular biology and management experience in the biotechnology and asset management industries. Dr. Goelet was educated at Oxford University and received an M.Phil and Ph.D. in biochemistry from the University of Cambridge, where he studied under Drs. Jonathan Karn and Sydney Brenner at the Laboratory of Molecular Biology. From 1984 to 1987, Dr. Goelet worked as a Helen Hay Whitney Fellow at Columbia University in the laboratory of Dr. Eric Kandel. Dr. Goelet has published several scientific articles and patents in the fields of nucleic acid chemistry, virology, neurobiology, genomics and drug discovery. Dr. Goelet is the co-founder and interim CEO of Dihedron Corporation, an oncology drug discovery company, and its affiliate, Acidophil, LLC, an intellectual property holding company that oversees the development of technologies invented by Dr. Goelet, Dr. Brenner and a group of scientific associates. Dr. Goelet served as an officer and director of the Rhode Island Corporation (a private investment company) and its successor, NORIC, from 1995 until its acquisition by Pogo Producing Company (NASDAQ: PPP) in 2001. Dr. Goelet was a co-founder of Ribotargets Holdings Plc. (an RNA structure-based drug discovery company) and served on its Board of Directors from 1997 to 2000. In 1990, Dr. Goelet co-founded Molecular Tool, Inc., where he co-invented SNP (single nucleotide polymorphism) analysis technology. As Chairman and CEO, Dr. Goelet completed Molecular Tool’s merger with GeneScreen, Inc. As a member of the Board of Directors of GeneScreen, Inc., he participated in its acquisition by Orchid Biosciences, Inc. (NASDAQ: ORCH), where he served on the Scientific Advisory Board. Dr. Goelet is a board member of the Boyce Thompson Institute of Plant Research, Ithaca, NY, and a member of the Senior Advisory Group for The Johns Hopkins Medicine Alliance for Science and Technology Development. | 